Comprehensive Library Of Resveratrol News

While the cancer research community is furiously working to develop synthetic micro-RNAs that will selectively kill cancer cells, the red wine molecule resveratrol appears to naturally activate a cancer kill switch that is being heralded today as an alternative to toxic chemotherapy.

Scientists now say they have found a sequence of three nucleotides (steps on the RNA ladder) that kill cancer cells by virtue of their ability to eliminate three survival genes.  The proposed treatment is called DISE (Death Induced by Survival Gene Elimination).

While researchers made worldwide headlines with this announcement today (Oct. 29, 2018) a duplicate report was released last year by the same research team.

The kill code is a natural inborn mechanism that could be utilized in place of chemotherapy, thus eliminating the toxic side effects associated with it.  Chemotherapy resistance is inevitable.  Tumors shrink until resistance sets it and then the tumor is unconquerable because the immune system is destroyed in the process.

The kill code is a sequence of six nucleotides (called 6mers) present in small micro-RNAs that are toxic to cancer cells without inducing treatment resistance.  While the research team says it is vigorously in pursuit to design artificial micro-RNAs, it turns out resveratrol is documented to activate micro-RNA34a which in turn triggers the very same cancer kill switch.

Resveratrol is well documented to limit cancer cell growth via microRNA-34a.

Cancer cells grow so rapidly they cannot be oxygenated properly and convert to utilizing sugars primarily for cell energy rather than oxygen.  Resveratrol is observed to activate microRNA-34a in an oxygen-less environment.  Resveratrol’s non-toxic effect is dependent upon dose.  Excessive doses promote oxidation and toxically (but selectively) kill cancer cells.  That there is a non-toxic mechanism activated by resveratrol that kills cancer cells before toxic doses need to be employed is of acute importance.

This anti-cancer mechanism, i.e. microRNA-34a activation by resveratrol, was first described in the medical literature in 2013.  ####